ProShare Advisors LLC Purchases 4,910 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX)

ProShare Advisors LLC lifted its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 41.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,814 shares of the company’s stock after purchasing an additional 4,910 shares during the period. ProShare Advisors LLC’s holdings in MeiraGTx were worth $102,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in MGTX. Summit Investment Advisors Inc. lifted its position in shares of MeiraGTx by 106.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company’s stock valued at $30,000 after purchasing an additional 2,515 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of MeiraGTx by 68.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company’s stock valued at $30,000 after purchasing an additional 2,016 shares in the last quarter. Polymer Capital Management US LLC bought a new position in shares of MeiraGTx during the fourth quarter valued at about $88,000. China Universal Asset Management Co. Ltd. lifted its position in shares of MeiraGTx by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,571 shares of the company’s stock valued at $101,000 after purchasing an additional 1,685 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of MeiraGTx by 41.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,976 shares of the company’s stock valued at $110,000 after purchasing an additional 5,259 shares in the last quarter. 67.48% of the stock is owned by institutional investors.

Insider Activity

In other news, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total value of $144,000.00. Following the sale, the chief financial officer now owns 882,494 shares of the company’s stock, valued at $5,294,964. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Alexandria Forbes sold 47,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $5.34, for a total transaction of $253,650.00. Following the completion of the sale, the chief executive officer now directly owns 1,408,983 shares in the company, valued at approximately $7,523,969.22. This trade represents a 3.26% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.50% of the company’s stock.

MeiraGTx Stock Performance

Shares of MGTX stock opened at $5.54 on Wednesday. The firm has a market cap of $445.22 million, a price-to-earnings ratio of -4.58, a P/E/G ratio of 0.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $8.75. The firm’s 50-day simple moving average is $5.74 and its two-hundred day simple moving average is $6.24.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.13). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The business had revenue of $1.93 million during the quarter, compared to the consensus estimate of $4.44 million. As a group, equities analysts forecast that MeiraGTx Holdings plc will post -1.48 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on MGTX. Chardan Capital lowered their price objective on shares of MeiraGTx from $38.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Royal Bank of Canada lifted their price objective on shares of MeiraGTx from $11.00 to $13.00 and gave the stock an “outperform” rating in a research report on Monday, March 17th. Finally, Wall Street Zen lowered shares of MeiraGTx from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.